搜索
Telix Pharmaceuticals Ltd
TLX添加自选
11.950USD
+0.640+5.66%
收盘 09-22 16:00（美东）
0.00总市值
0.00市盈率 TTM
盘前交易 05:27 (美东)11.570USD-0.380-3.18%
盘前交易 05:27 (美东)关于 Telix Pharmaceuticals Ltd 公司
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Telix Pharmaceuticals Ltd 简介
公司代码TLX
公司名称Telix Pharmaceuticals Ltd
上市日期Nov 15, 2017
CEOOrtiz (Raphaeel)
员工数量- -
证券类型Depository Receipt
年结日- -
公司地址55 Flemington Road
城市MELBOURNE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Australia
邮编3051
电话61390933855
网址https://telixpharma.com/
公司代码TLX
上市日期Nov 15, 2017
CEOOrtiz (Raphaeel)
Telix Pharmaceuticals Ltd公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Cade, M.D.
Dr. David Cade, M.D.
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Darren Smith, CPA
Mr. Darren Smith, CPA
Group Chief Financial Officer
Group Chief Financial Officer
--
--
Dr. Darren Patti, Pharm.D.
Dr. Darren Patti, Pharm.D.
Group Chief Operating Officer
Group Chief Operating Officer
--
--
Ms. Marie McDonald
Ms. Marie McDonald
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. David Gill
Mr. David Gill
Non-Executive Chair of the Board
Non-Executive Chair of the Board
--
--
Ms. Shomalin Naidoo
Ms. Shomalin Naidoo
Interim Company Secretary
Interim Company Secretary
--
--
Dr. Maria Rivas, M.D.
Dr. Maria Rivas, M.D.
Additional Non-Executive Director
Additional Non-Executive Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Cade, M.D.
Dr. David Cade, M.D.
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Darren Smith, CPA
Mr. Darren Smith, CPA
Group Chief Financial Officer
Group Chief Financial Officer
--
--
Dr. Darren Patti, Pharm.D.
Dr. Darren Patti, Pharm.D.
Group Chief Operating Officer
Group Chief Operating Officer
--
--
常见问题
Telix Pharmaceuticals Ltd的前五大股东是谁？
Telix Pharmaceuticals Ltd 的前五大股东如下：Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
有多少机构持有Telix Pharmaceuticals Ltd(TLX)的股份？
截至2026Q1，共有61家机构持有Telix Pharmaceuticals Ltd的股份，合计持有的股份价值约为1.47M，占公司总股份的0.43%。与2025Q4相比，机构持股有所增加，增幅为326197.00。